If There Were 2,700 Lawsuits Against Electronic Cigarette Manufacturers, Would E-Cigs Stay on the Market? Anti-Smoking Groups Continue to Recommend Chantix Despite 2,700 Lawsuits and in Absence of Determining Validity of Claims
If there were 2,700 filed in the U.S. against electronic cigarette manufacturers for alleged severe consequences including suicide and attempted suicide, e-cigs wouldn't remain on the market for 24 hours. Even the possibility that e-cigs may have caused 2,700 deaths would be enough to force these products off the market.Yet despite the more than 3,000 lawsuits filed against Pfizer for alleged fatal or near fatal consequences of its smoking cessation drug Chantix, anti-smoking groups continue to recommend this drug for widespread use.Even worse, the anti-smoking groups are encouraging the use of Chantix in the absence of an...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - March 12, 2013 Category: Health Medicine and Bioethics Commentators Source Type: blogs
The Industrial Diels Alder, Revisited in Detail
Last year I mentioned the "good ol' Diels-Alder reaction", and talked about how it doesn't get used as much in drug discovery and industrial chemistry as one might think.
Now Stefan Abele from Actelion (in Switzerland) sends along this new paper, which will tell you pretty much all you need to know about the reaction's industrial side. The scarcity of D-A chemistry on scale that I'd noticed was no illusion (links below added by me):
According to a survey by Dugger et al. in 2005 of the type of reaction scaled in a research facility at Pfizer, and an analysis of the reactions used for the preparation of drug candidate mo...
Source: In the Pipeline - February 28, 2013 Category: Chemists Tags: Chemical News Source Type: blogs
Novartis Gives Up On Nicotine Vaccine
Another one bites the dust.
Novartis, a leading health care products company, called it quits on its NIC002 nicotine vaccine project, which failed badly three years ago in Phase II studies undertaken with an eye toward government approval. Novartis said it would terminate the license it has for the NIC002 vaccine with Cytos Biotechnology, for which it paid $38 million in 2007. The Phase II study “showed formation of nicotine-specific antibodies in patients but did not meet its primary endpoint of increased smoking cessation,” according to Genetic Engineering and Biotechnology News
Much the same arc was followed by N...
Source: Addiction Inbox - January 27, 2013 Category: Addiction Authors: Dirk Hanson Source Type: blogs
Usefulness in Smoking Cessation or Reduction is Not Necessarily a Therapeutic Claim; Electronic Cigarette Companies Should Be Allowed to Tell the Truth
In his blog post last Thursday, Stan Glantz argued that electronic cigarette companies should not be allowed to claim that these products can be useful for smoking cessation or reduction because such claims would represent "therapeutic" or "drug" claims and therefore put the products under the jurisdiction of the Food, Drug, and Cosmetic Act (FDCA).Glantz wrote: "The fact that the e-cigarette companies and their trade association have been encouraging their consumers to submit public comments to a docket about smoking cessation products can be read no other way than the e-cigarette companies and their trade association ...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - January 22, 2013 Category: Health Medicine and Bioethics Commentators Source Type: blogs
FDA Will Issue Proposed Regulations for Electronic Cigarettes in April
According to a Troutman Sanders article, the Obama administration has announced that the FDA will issue proposed regulations for electronic cigarettes (as well as cigars, pipe tobacco, and other tobacco products) this April. While the Family Smoking Prevention and Tobacco Control Act created a regulatory framework for cigarettes and smokeless tobacco, it did not establish provisions for other types of tobacco products. The FDA intends to fill this gap by issuing regulations for these other products.The Rest of the StoryThere are several critical aspects of the regulation that I will be closely watching with regard to the r...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - January 10, 2013 Category: Health Medicine and Bioethics Commentators Source Type: blogs
